Corrigendum to ‘Toll-like receptors Expression and involvement in Multiple Myeloma’ [Leukemia Research 34 (2010)1545-1550] (Toll-like receptors: Expression and involvement in Multiple Myeloma (2010) 34(12) (1545–1550), (S0145212610002912), (10.1016/j.leukres.2010.06.002));Toll-like receptors: Expression and involvement in Multiple Myeloma

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1545-1550

  Chiron, David ^a,b   Jego, Gaetan ^c,d   Pellat Deuceunynck, Catherine ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Chu   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Heterogeneity; Immune system; Infections; Myeloma; Toll like receptors

Indexed keywords

ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MULTIPLE MYELOMA; MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 78149361152     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2017.11.003     Document Type: Erratum

References (50)

1. Raab M.S., Podar K., Breitkreutz I., et al. Multiple myeloma. Lancet 2009, 374:324-339.
2. Kyle R.A., Kumar S. The significance of monoclonal gammopathy of undetermined significance. Haematologica 2009, 94:1641-1644.
3. Dispenzieri A., Kyle R.A. Multiple myeloma: clinical features and indications for therapy. Best Practice & Research Clinical Haematology 2005, 18:553-568.
4. Brown L.M., Gridley G., Check D., Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008, 111:3388-3394.
5. Landgren O., Rapkin J.S., Mellemkjaer L., et al. Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. Haematologica 2006, 91:1697-1700.
6. Krieg A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008, 27:161-167.
7. Huang B., Zhao J., Unkeless J.C., et al. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008, 27:218-224.
8. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nature Reviews. Cancer 2009, 9:57-63.
9. Chiron D., Bekeredjian-Ding I., Pellat-Deceunynck C., et al. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 2008, 112:2205-2213.
10. Beg A.A. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends in Immunology 2002, 23:509-512.
11. Apetoh L., Ghiringhelli F., Tesniere A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine 2007, 13:1050-1059.
12. Yanai H., et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009, 462:99-103.
13. Johnson G.B., et al. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. Journal of Immunology (Baltimore, Md.: 1950) 2002, 168:5233-5239.
14. Lovell R., Dunn J.A., Gulnaz B., et al. Soluble syndecan-1 level at diagnosis is an independent prognostis factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. British Journal of Haematology 2005, 130:542-548.
15. Kawai T., Akira S. Signaling to NF-[kappa]B by Toll-like receptors. Trends in Molecular Medicine 2007, 13:460-469.
16. Chen H., Li M., Campbell R.A., et al. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene 2006, 25:6520-6527.
17. Liu J., Hamrouni A., Wolowiec D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-TRAF6-, and MEK-dependent pathway. Blood 2007, 110:296-304.
18. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
19. Bohnhorst J., Rasmussen T., Moen S.H., et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006, 20:1138-1144.
20. Jego G., Bataille R., Geffroy-Luseau A., et al. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006, 20:130-1137.
21. Bekeredjian-Ding I., Jego G. Toll-like receptors-sentries in the B-cell response. Immunobiology 2009, 128:311-323.
22. Dorner M., Brandt S., Tinguely M., et al. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 2009, 128:573-579.
23. Zhan F., Huang Y., Colla S., et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.
24. Okamoto M., Furuichi S., Nishioka Y., et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Research 2004, 64:5461-5470.
25. Tsuji S., Matsumoto M., Takeuchi O., et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infection and Immunity 2000, 68:6883-6890.
26. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunological Reviews 2004, 199:227-250.
27. Bekeredjian-Ding I., Doster A., Schiller M., et al. TLR9-activating DNA up-regulates ZAP70 via sustained PKB induction in IgM+ B cells. Journal of Immunology (Baltimore, Md.: 1950) 2008, 181:8267-8277.
28. Pratt G., Goodyear O., Moss P. Immunodeficiency and immunotherapy in multiple myeloma. British Journal of Haematology 2007, 138:563-579.
29. Chauhan D., Singh A.V., Brahmandam M. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009, 16:309-323.
30. Assaf A., Esteves H., Curnow S.J., Browning M.J. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines. Cellular Immunology 2009, 259:90-99.
31. Krieg A.M. Development of TLR9 agonists for cancer therapy. The Journal of Clinical Investigation 2007, 117:1184-1194.
32. Chiron D., Pellat-Deceunynck C., Maillasson M., et al. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. Journal of Immunology (Baltimore, Md.: 1950) 2009, 183:4371-4377.
33. Guvakova M.A., Yakubov L.A., Vlodavsky I., et al. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. The Journal of Biological Chemistry 1995, 270:2620-2627.
34. Salaun B., Romero P., Lebecque S. Toll-like receptors' two-edged sword: when immunity meets apoptosis. European Journal of Immunology 2007, 37:3311-3318.
35. Paone A., Starace D., Galli R., et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008, 29:1334-1342.
36. Salaun B., Lebecque S., Matikainen S., et al. Toll-like receptor 3 expressed by melanoma cells as a target for therapy?. Clinical Cancer Research 2007, 13:4565-4574.
37. Sivori S., Falco M., Della Chiesa M., et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:10116-10121.
38. Chiron D., Pellat-Deceunynck C., Amiot M., et al. TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. Journal of Immunology (Baltimore, Md.: 1950) 2009, 182:4471-4478.
39. Osawa Y., Iho S., Takauji R., et al. Collaborative action of NF-kappaB and p38 MAPK is involved in CpG DNA-induced IFN-alpha and chemokine production in human plasmacytoid dendritic cells. Journal of Immunology (Baltimore, Md.: 1950) 2006, 177:4841-4852.
40. The Myeloma Trialists' Collaborative Group Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. British Journal of Haematology 2001, 113:1020-1034.
41. Durie B.G., Levy H.B., Voakes J., et al. Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma. Journal of Biological Response Modifiers 1985, 4:518-524.
42. Kawano M., Hirano T., Matsuda T., et al. Autocrine generation and requirement of BSF-2/IL-6IL6 for human multiple myelomas. Nature 1988, 332:83-85.
43. Klein B., Zhang X.G., Jourdan M., et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989, 73:517-526.
44. Bataille R., Jourdan M., Zhang X.G., Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. The Journal of Clinical Investigation 1989, 84:2008-2011.
45. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine 2002, 8:793-800.
46. Sun D., Ding A. MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA. Nature Immunology 2006, 7(4):375-381.
47. Romagnoli M., Desplanques G., Maïga S., et al. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clinical Cancer Research 2007, 13:6010-6018.
48. Tai Y., Li X., Breitkreutz I., et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Research 2006, 66:6675-6682.
49. Killeen S.D., et al. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?. British Journal of Cancer 2006, 95:247-252.
50. Le Carrour T., Assou S., Tondeur S., Lhermitte L., Lamb N., Reme T., Pantesco V., Hamamah S., Klein B., De Vos J. Amazonia!: an online resource to Google and visualize public human whole genome expression data. The Open Bioinformatics Journal 2010, 4:5-10.